Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p

Figure 3

Dexrazoxane alleviates doxorubicin-mediated cytotoxicity and cardiomyocytes apoptosis. (a,b) The expression of caspase 3 and cleaved caspase 3 in cardiomyocytes pretreated with different concentrations of dexrazoxane (0, 20, 100, 200, 300, and 400 μM) for 1 h, then treated with or without 1 μM doxorubicin (, versus Con group; #, ## versus DOX group). (c) The cell viability was estimated by MTT assay in Con, DOX, DOX+DEX, and DEX groups (). (d) LDH concentration in the medium after treated with or without dexrazoxane and doxorubicin (). (e,f) Hoechst staining for Con, DOX, DOX+DEX, and DEX groups (). (g) DNA laddering for Con, DOX, DOX+DEX, and DEX groups. (h–l) Caspase 3, cleaved-caspase 3, Bax, phosphorylated-p38MAPK, p38MAPK, phosphorylated-p65, p65, and GAPDH in cardiomyocyte treated with or without 200 μM dexrazoxane and 1 μM doxorubicin (). (, , ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)